HIV integrase inhibitors block replication of Alpha-, Beta-, and gammaherpesviruses

mBio

Volumn 5, Issue 4, 2014, Pages

  Yan, Zhipeng ^a,d   Bryant, Kevin F ^a,e   Gregory, Sean M ^a,f   Angelova, Magdalena ^a   Dreyfus, David H ^b   Zhao, Xue Zhi ^c   Coen, Donald M ^a   Burke, Terrence R ^c   Knipe, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Roche Research and Development Center (China) Ltd   (China)

^e Active Motif   (United States)

^f BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

118 D24; HYDRAZIDE DERIVATIVE; INFECTED CELL PROTEIN 8; INTEGRASE INHIBITOR; ISOINDOLE DERIVATIVE; OXOACID; PYRIDONE DERIVATIVE; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION; DRUG POTENCY; DRUG SCREENING; FETUS; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; IN VITRO STUDY; NONHUMAN; SKIN FIBROBLAST; VIRUS INDUCTION; VIRUS REACTIVATION; VIRUS RECOMBINATION; VIRUS REPLICATION; CELL LINE; CYTOMEGALOVIRUS; DRUG EFFECTS; SIMPLEXVIRUS;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS 8, HUMAN; HIV INTEGRASE INHIBITORS; HUMANS; SIMPLEXVIRUS; VIRUS REPLICATION;

EID: 84908238891     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01318-14     Document Type: Article

References (45)

1. Roizman B, Knipe DM, Whitley RJ. 2013. Herpes simplex viruses, p 1823-1897. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Coen DM, Richman DD. 2013. Antiviral agents, p 338-374. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. van Velzen M, van de Vijver DA, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM. 2013. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J. Infect. Dis. 208: 1359-1365. http://dx.doi.org/10.1093/infdis/jit350.
4. Pan D, Kaye SB, Hopkins M, Kirwan R, Hart IJ, Coen DM. 2014. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J. Infect. Dis. 209:345-349. http://dx.doi.org/10.1093/infdis/jit437.
5. Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A. 2014. Helicase-primase inhibitor pritelivir for HSV-2 infection. N. Engl. J. Med. 370:201-210. http://dx.doi.org/10.1056/NEJMoa1301150.
6. Freed E, Martin M. 2013. Human immunodeficiency viruses: replication, p 1502-1561. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
7. Di Santo R. 2014. Inhibiting the HIV integration process: past, present, and the future. J. Med. Chem. 57:539-566. http://dx.doi.org/10.1021/jm400674a.
8. Cherepanov P, Maertens GN, Hare S. 2011. Structural insights into the retroviral DNA integration apparatus. Curr. Opin. Struct. Biol. 21: 249-256. http://dx.doi.org/10.1016/j.sbi.2010.12.005.
9. Selvarajan Sigamani S, Zhao H, Kamau YN, Baines JD, Tang L. 2013. The structure of the herpes simplex virus DNA-packaging terminase pUL15 nuclease domain suggests an evolutionary lineage among eukaryotic and prokaryotic viruses. J. Virol. 87:7140-7148. http://dx.doi.org/10.1128/JVI.00311-13.
10. Nadal M, Mas PJ, Blanco AG, Arnan C, Solà M, Hart DJ, Coll M. 2010. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc. Natl. Acad. Sci. U. S. A. 107:16078-16083. http://dx.doi.org/10.1073/pnas.1007144107.
11. Bryant KF, Yan Z, Dreyfus DH, Knipe DM. 2012. Identification of a divalent metal cation binding site in herpes simplex virus 1 (HSV-1) ICP8 required for HSV replication. J. Virol. 86:6825-6834. http://dx.doi.org/10.1128/JVI.00374-12.
12. Dreyfus DH. 2009. Paleo-immunology: evidence consistent with insertion of a primordial herpes virus-like element in the origins of acquired immunity. PLoS One 4:e5778. http://dx.doi.org/10.1371/journal.pone.0005778.
13. Nimonkar AV, Boehmer PE. 2003. The herpes simplex virus type-1 single-strand DNA-binding protein (ICP8) promotes strand invasion. J. Biol. Chem. 278:9678-9682. http://dx.doi.org/10.1074/jbc.M212555200.
14. Reuven NB, Staire AE, Myers RS, Weller SK. 2003. The herpes simplex virus type 1 alkaline nuclease and single-stranded DNA binding protein mediate strand exchange in vitro. J. Virol. 77:7425-7433. http://dx.doi.org/10.1128/JVI.77.13.7425-7433.2003.
15. Conley AJ, Knipe DM, Jones PC, Roizman B. 1981. Molecular genetics of herpes simplex virus. VII. Characterization of a temperature-sensitive mutant produced by in vitro mutagenesis and defective in DNA synthesis and accumulation of gamma polypeptides. J. Virol. 37:191-206.
16. Baines JD, Poon AP, Rovnak J, Roizman B. 1994. The herpes simplex virus 1 U(L)15 gene encodes two proteins and is required for cleavage of genomic viral DNA. J. Virol. 68:8118-8124.
17. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515. http://dx.doi.org/10.1097/QAI.0b013e31802b4956.
18. Zhangm X, Pais GC, Svarovskaia ES, Marchand C, Johnson AA, Karki RG, Nicklaus MC, Pathak VK, Pommier Y, Burke TR. 2003. Azidocontaining aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 24:1215-1219.
19. Zhao XZ, Semenova EA, Vu BC, Maddali K, Marchand C, Hughes SH, Pommier Y, Burke TR. 2008. 2,3-Dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. J. Med. Chem. 51:251-259. http://dx.doi.org/10.1021/jm070715d.
20. Pellett P, Roizman B. 2013. Herpesviridae, p 1802-1823. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
21. Ozgur S, Damania B, Griffith J. 2011. The Kaposi’s sarcoma-associated herpesvirus ORF6DNAbinding protein forms long DNA-free helical protein filaments. J. Struct. Biol. 174:37-43. http://dx.doi.org/10.1016/j.jsb.2010.10.015.
22. Deng B, O’Connor CM, Kedes DH, Zhou ZH. 2007. Direct visualization of the putative portal in the Kaposi’s sarcoma-associated herpesvirus capsid by cryoelectron tomography. J. Virol. 81:3640-3644. http://dx.doi.org/10.1128/JVI.02254-06.
23. Shin HJ, DeCotiis J, Giron M, Palmeri D, Lukac DM. 2014. Histone deacetylase classes I and II regulate Kaposi’s sarcoma-associated herpesvirus reactivation. J. Virol. 88:1281-1292. http://dx.doi.org/10.1128/JVI.02665-13.
24. Andrei G, Snoeck R. 2013. Herpes simplex virus drug-resistance: new mutations and insights. Curr. Opin. Infect. Dis. 26:551-560. http://dx.doi.org/10.1097/QCO.0000000000000015.
25. Dreyfus DH. 2013. Evidence that raltegravir (Isentress, Merck), a retroviral integrase inhibitor is effective against recurrent human herpes simplex virus infection associated with NK-cell deficiency. Pediatr. Ther. 3:172. http://dx.doi.org/10.4172/2161-0665.1000172.
26. Challberg MD. 1986. A method for identifying the viral genes required for herpesvirusDNAreplication. Proc. Natl. Acad. Sci. U. S. A. 83:9094-9098. http://dx.doi.org/10.1073/pnas.83.23.9094.
27. Roizman B, Jacob RJ, Knipe DM, Morse LS, Ruyechan WT. 1979. On the structure, functional equivalence, and replication of the four arrangements of herpes simplex virus DNA. Cold Spring Harb. Symp. Quant. Biol. 43:809-826.
28. Nimonkar AV, Boehmer PE. 2003. Reconstitution of recombinationdependent DNA synthesis in herpes simplex virus 1. Proc. Natl. Acad. Sci. U. S. A. 100:10201-10206. http://dx.doi.org/10.1073/pnas.1534569100.
29. Wilkinson DE, Weller SK. 2003. The role of DNA recombination in herpes simplex virus DNA replication. IUBMB Life 55:451-458. http://dx.doi.org/10.1080/15216540310001612237.
30. Gao M, Knipe DM. 1991. Potential role for herpes simplex virus ICP8 DNA replication protein in stimulation of late gene expression. J. Virol. 65:2666-2675.
31. Mavromara-Nazos P, Roizman B. 1987. Activation of herpes simplex virus 1 gamma 2 genes by viral DNA replication. Virology 161:593-598. http://dx.doi.org/10.1016/0042-6822(87)90156-5.
32. Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, Lee S, Buckley JD, Laird PW, Marquez VE, Jung JU. 2010. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog. 6:e1001013. http://dx.doi.org/10.1371/journal.ppat.1001013.
33. Knipe DM, Lieberman PM, Jung JU, McBride AA, Morris KV, Ott M, Margolis D, Nieto A, Nevels M, Parks JR, Kristie TM. 2013. Snapshots: Chromatin control of viral infection. Virology 435:141-156. http://dx.doi.org/10.1016/j.virol.2012.09.023.
34. Hall CB, Caserta MT, Schnabel K, Shelley LM, Marino AS, Carnahan JA, Yoo C, Lofthus GK, McDermott MP. 2008. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics 122:513-520. http://dx.doi.org/10.1542/peds.2007-2838.
35. Gulley ML, Raphael M, Lutz CT, Ross DW, Raab-Traub N. 1992. Epstein-Barr virus integration in human lymphomas and lymphoid cell lines. Cancer 70:185-191. http://dx.doi.org/10.1002/1097-0142(19920701)70:1_185::AID-CNCR2820700129_3.0.CO;2-J.
36. Delecluse HJ, Schüller S, Hammerschmidt W. 1993. Latent Marek’s disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells. EMBO J. 12:3277-3286.
37. Luppi M, Marasca R, Barozzi P, Ferrari S, Ceccherini-Nelli L, Batoni G, Merelli E, Torelli G. 1993. Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J. Med. Virol. 40:44-52. http://dx.doi.org/10.1002/jmv.1890400110.
38. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. 2000. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J. Virol. 74:7963-7971. http://dx.doi.org/10.1128/JVI.74.17.7963-7971.2000.
39. Inn KS, Lee SH, Rathbun JY, Wong LY, Toth Z, Machida K, Ou JH, Jung JU. 2011. Inhibition of RIG-I-mediated signaling by Kaposi’s sarcoma-associated herpesvirus-encoded deubiquitinase ORF64. J. Virol. 85:10899-10904. http://dx.doi.org/10.1128/JVI.00690-11.
40. Schaffer P, Vonka V, Lewis R, Benyesh-Melnick M. 1970. Temperaturesensitive mutants of herpes simplex virus. Virology 42:1144-1146. http://dx.doi.org/10.1016/0042-6822(70)90364-8.
41. Ejercito PM, Kieff ED, Roizman B. 1968. Characterization of herpes simplex virus strains differing in their effect on social behavior of infected cells. J. Gen. Virol. 2:357-364. http://dx.doi.org/10.1099/0022-1317-2-3-357.
42. Gao M, Knipe DM. 1989. Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J. Virol. 63: 5258-5267.
43. Zhu LA, Weller SK. 1992. The UL5 gene of herpes simplex virus type 1: isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex. J. Virol. 66: 458-468.
44. Strang BL, Boulant S, Chang L, Knipe DM, Kirchhausen T, Coen DM. 2012. Human cytomegalovirus UL44 concentrates at the periphery of replication compartments, the site of viral DNA synthesis. J. Virol. 86: 2089-2095. http://dx.doi.org/10.1128/JVI.06720-11.
45. Knipe DM, Quinlan MP, Spang AE. 1982. Characterization of two conformational forms of the major DNA-binding protein encoded by herpes simplex virus 1. J. Virol. 44:736-741.